Course: Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2
CME Credits: 1.00
Released: 2021-09-01
On December 20, 2020, Israel initiated a national vaccination program against COVID-19. National and international vaccine guidelines did not preclude patients who have previously been diagnosed with Guillain-Barré Syndrome (GBS) from receiving the COVID-19 vaccine., However, previous association between vaccines and GBS raises the level of caution and hesitancy among clinicians and patients regarding administering the vaccine.- The aim of this study was to establish rates of GBS relapse among Pfizer-BioNTech BNT162b2 vaccine receivers.
Educational Objective
To identify the key insights or developments described in this article
View Full Course